At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed stage IV NSCLC
- ✓BRAFV600 mutation (V600E or other variants K or D)
- ✓Treatment-naïve OR prior platinum-based chemotherapy OR prior PD-1/PD-L1 inhibitor (given alone or with platinum)
- ✓Measurable disease per RECIST v1.1
- ✕EGFR mutation, ALK fusion, or ROS1 rearrangement
- ✕More than 1 prior line of systemic therapy in advanced/metastatic setting
- ✕Prior BRAF inhibitor or MEK inhibitor
- ✕Impaired cardiovascular function or clinically significant cardiovascular disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating encorafenib and binimetinib for Non-small Cell Lung Cancer. Completed, enrolled 98 participants across 143 sites in 5 countries.
Detailed Summary
This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.
Study Details
Timeline
Interventions
self-administered orally
self-administered orally